Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Artemether-lumefantrine · 1 trial · 1 indication
ACPR (PCR-corrected) was defined as asexual Plasmodium falciparum (P.falciparum) parasitologic clearance at Day 28 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of Early Treatment Failure (ETF) (see measure description in secondary outcome measures 7 and 8) or PCR-corrected Late Treatment Failure (LTF) (which includes PCR-corrected Late Clinical Failures \[LCF\] - see measure description in secondary outcome measure 9 and 10, and PCR-corrected Late Parasitologic Failures (LPF)- see measure description in secondary outcome measure 11 and 12). PCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.
ACPR (PCR-corrected) was defined as asexual P.falciparum parasitologic clearance at Day 28 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or PCR-corrected LTF (which includes PCR-corrected LCF - see measure description in secondary outcome measure 9 and 10, and PCR-corrected LPF - see measure description in secondary outcome measure 11 and 12). PCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Azithromycin plus Chloroquine | DRUG | Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2) |
| Artemether-lumefantrine | DRUG | Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2) |
Inclusion Criteria: * Girls and boys ≥5 years to ≤12 years (Cohort 1); and ≥6 to ≤59 months of age (Cohort 2) with uncomplicated, symptomatic malaria as indicated by the presence of the following: * Blood smears positive for monoinfection with P. falciparum and asexual parasitemia between 1000 -100...
Artemether-lumefantrine is used for the treatment of uncomplicated Plasmodium falciparum malaria. It is being studied in children in Africa, specifically for this indication. The drug is a small molecule and is currently in Phase 2 clinical development.
Artemether-lumefantrine is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials for this drug in the treatment of falciparum malaria.
Artemether-lumefantrine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed for this drug.
Artemether-lumefantrine has one completed clinical trial, NCT00677833, which was a Phase 2 study. The trial evaluated azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated P. falciparum malaria in children in Africa.
Artemether-lumefantrine is a combination antimalarial drug. It targets the malaria parasite Plasmodium falciparum, specifically the asexual blood stages of the parasite, to treat uncomplicated malaria infections.